Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC By Ogkologos - September 17, 2026 84 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a second planned interim analysis of the AEGEAN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Firefighters Band Together To Raise $30k For Breast Cancer Research &... September 24, 2021 Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 Coffee Shop Owner Runs Competitor’s Business For Free After Hearing He... December 18, 2019 Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... April 6, 2023 Load more HOT NEWS What Should People With Cancer Know About Alkaline Water? 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... Are Cancer Patients Getting the Opioids They Need to Control Pain? Aspartame and cancer – sweet nothings?
